BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1345 related articles for article (PubMed ID: 11413351)

  • 1. Decreased bronchodilating effect of salbutamol in relieving methacholine induced moderate to severe bronchoconstriction during high dose treatment with long acting beta2 agonists.
    van der Woude HJ; Winter TH; Aalbers R
    Thorax; 2001 Jul; 56(7):529-35. PubMed ID: 11413351
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A high dose of albuterol does not overcome bronchoprotective subsensitivity in asthmatic subjects receiving regular salmeterol or formoterol.
    Lipworth BJ; Aziz I
    J Allergy Clin Immunol; 1999 Jan; 103(1 Pt 1):88-92. PubMed ID: 9893190
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of formoterol, salbutamol and salmeterol in methacholine-induced severe bronchoconstriction.
    Politiek MJ; Boorsma M; Aalbers R
    Eur Respir J; 1999 May; 13(5):988-92. PubMed ID: 10414394
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Onset of relief of dyspnoea with budesonide/formoterol or salbutamol following methacholine-induced severe bronchoconstriction in adults with asthma: a double-blind, placebo-controlled study.
    Jonkers RE; Bantje TA; Aalbers R
    Respir Res; 2006 Dec; 7(1):141. PubMed ID: 17144916
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relief of dyspnoea by beta2-agonists after methacholine-induced bronchoconstriction.
    van der Woude HJ; Postma DS; Politiek MJ; Winter TH; Aalbers R
    Respir Med; 2004 Sep; 98(9):816-20. PubMed ID: 15338791
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Unaltered perception of dyspnoea during treatment with long-acting beta2-agonists.
    van der Woude HJ; Aalbers R
    Eur Respir J; 2001 Aug; 18(2):269-71. PubMed ID: 11529283
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhaled corticosteroids do not prevent the development of tolerance to the bronchoprotective effect of salmeterol.
    Kalra S; Swystun VA; Bhagat R; Cockcroft DW
    Chest; 1996 Apr; 109(4):953-6. PubMed ID: 8635376
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Budesonide/formoterol in a single inhaler rapidly relieves methacholine-induced moderate-to-severe bronchoconstriction.
    van der Woude HJ; Boorsma M; Bergqvist PB; Winter TH; Aalbers R
    Pulm Pharmacol Ther; 2004; 17(2):89-95. PubMed ID: 15123230
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Functional antagonism with formoterol and salmeterol in asthmatic patients expressing the homozygous glycine-16 beta(2)-adrenoceptor polymorphism.
    Lipworth BJ; Dempsey OJ; Aziz I
    Chest; 2000 Aug; 118(2):321-8. PubMed ID: 10936119
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vivo effect of albuterol on methacholine-contracted bronchi in conjunction with salmeterol and formoterol.
    Aziz I; Lipworth BJ
    J Allergy Clin Immunol; 1999 May; 103(5 Pt 1):816-22. PubMed ID: 10329815
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of long-acting and short-acting beta-agonists on methacholine dose-response curves in asthmatics.
    Wong AG; O'Shaughnessy AD; Walker CM; Sears MR
    Eur Respir J; 1997 Feb; 10(2):330-6. PubMed ID: 9042628
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dose equivalence and bronchoprotective effects of salmeterol and salbutamol in asthma.
    Higham MA; Sharara AM; Wilson P; Jenkins RJ; Glendenning GA; Ind PW
    Thorax; 1997 Nov; 52(11):975-80. PubMed ID: 9487346
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A comparison of salmeterol and formoterol in attenuating airway responses to short-acting beta2-agonists.
    van Veen A; Weller FR; Wierenga EA; Jansen HM; Jonkers RE
    Pulm Pharmacol Ther; 2003; 16(3):153-61. PubMed ID: 12749831
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tolerance to bronchodilation during treatment with long-acting beta-agonists, a randomised controlled trial.
    Haney S; Hancox RJ
    Respir Res; 2005 Sep; 6(1):107. PubMed ID: 16168062
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhaled dry-powder formoterol and salmeterol in asthmatic patients: onset of action, duration of effect and potency.
    Palmqvist M; Persson G; Lazer L; Rosenborg J; Larsson P; Lötvall J
    Eur Respir J; 1997 Nov; 10(11):2484-9. PubMed ID: 9426083
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Acute protection against exercise-induced bronchoconstriction by formoterol, salmeterol and terbutaline.
    Richter K; Janicki S; Jörres RA; Magnussen H
    Eur Respir J; 2002 May; 19(5):865-71. PubMed ID: 12030726
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Protective effect of budesonide/formoterol compared with formoterol, salbutamol and placebo on repeated provocations with inhaled AMP in patients with asthma: a randomised, double-blind, cross-over study.
    Aalbers R; Boorsma M; van der Woude HJ; Jonkers RE
    Respir Res; 2010 May; 11(1):66. PubMed ID: 20509942
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Standard technical specifications for methacholine chloride (Methacholine) bronchial challenge test (2023)].
    ; ;
    Zhonghua Jie He He Hu Xi Za Zhi; 2024 Feb; 47(2):101-119. PubMed ID: 38309959
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rapid onset of tolerance to the bronchoprotective effect of salmeterol.
    Bhagat R; Kalra S; Swystun VA; Cockcroft DW
    Chest; 1995 Nov; 108(5):1235-9. PubMed ID: 7587422
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of the relative efficacy of formoterol and salmeterol in asthmatic patients.
    Palmqvist M; Ibsen T; Mellén A; Lötvall J
    Am J Respir Crit Care Med; 1999 Jul; 160(1):244-9. PubMed ID: 10390407
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 68.